3'-Deoxy-3'(18) F-Fluorothymidine Positron Emission Tomography/Computed Tomography (PET/CT) for Initial Staging, Radiotherapy Target Definition, and Assessment of Response to Therapy in Patients With Esophageal Cancer: A Pilot Study
- The following are standard medical procedures that are part of regular cancer care that
the participant would probably have done even if they did not join the study:
Chemotherapy; physical examination; pregnancy test (if applicable); diagnostic
FDG-PET/CT scan before and after treatment to evaluate disease.
- The following diagnostic procedures are being done specifically because of this study:
Three FLT-PET/CT scans before, during and after treatment and one FDG PET/CT scan
- Participants will be in this research study for approximately 12-14 weeks.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Determine possibility of acquiring three sets of serial PET scans, and importing the images for analysis.
Determine the possibility of aquiring three sets of serial Positron emission tomography (PET) scans from 5 patients at designated time points and to develop a mechanism to import and analyze images from F-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT)-PET, F-Fluorodeoxyglucose(FDG)-PET and Computed Tomography (CT) on a single advanced software platform with deformable image registration capability. We will report patient acceptance of and compliance with this regimen, as well as the utility of the software platform for conducting the proposed analysis.
Harvey J. Mamon, MD, PhD
Brigham and Women's Hospital/Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|